Covid 19 Research using Clinical Trials (Home Page)
Report for D003928: Diabetic Nephropathies NIH
(Synonyms: Diabetic Nephropa, Diabetic Nephropathi, Diabetic Nephropathies)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
There is one clinical trial.
Clinical Trials
1 CSP #2008 - Pentoxifylline in Diabetic Kidney Disease
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.
NCT03625648 Diabetic Kidney Disease Drug: Pentoxifylline Drug: Placebo MeSH:Kidney Diseases Diabetic Nephropathies
HPO:Abnormality of the kidney Nephropathy
Primary Outcomes
Description: ESRD will be defined as need for chronic dialysis or renal transplantation.
Measure: Time to ESRD or death Time: 5 to 9 years
Secondary Outcomes
Description: Quality of life as measured by the Kidney Disease Quality of Life Short Form (KDQoL-SF)
Measure: Quality of life (KDQoL-SF) Time: 5 to 9 years
Description: Time until doubling of serum creatinine
Measure: Time until doubling of serum creatinine Time: 5 to 9 years
Description: The risk of a CHF hospitalization will be based on the participant-time data, specifically, the number of events per years.
Measure: Incidence of congestive heart failure hospitalization (CHF) Time: 5 to 9 years
Description: The risk of a MACE event will be based on participant-time data, specifically, the number of events per participant years.
Measure: Incidence of a three-point MACE Time: 5 to 9 years
Description: The risk of a PVD event will be based on participant-time data, specifically, the number of events per participant years.
Measure: Incidence of a peripheral vascular disease (PVD) Time: 5 to 9 years
Description: Percentage of participants with 50% reduction in UACR from baseline
Measure: Percentage of participants with 50% reduction in UACR from baseline Time: 5 to 9 years
Description: Rate of change in eGFR per year during the study period.
Measure: Rate of change in eGFR per year during the study period Time: 5 to 9 years
HPO Nodes
Primary Outcomes
Description: ESRD will be defined as need for chronic dialysis or renal transplantation.
Measure: Time to ESRD or death Time: 5 to 9 yearsSecondary Outcomes
Description: Quality of life as measured by the Kidney Disease Quality of Life Short Form (KDQoL-SF)
Measure: Quality of life (KDQoL-SF) Time: 5 to 9 yearsDescription: Time until doubling of serum creatinine
Measure: Time until doubling of serum creatinine Time: 5 to 9 yearsDescription: The risk of a CHF hospitalization will be based on the participant-time data, specifically, the number of events per years.
Measure: Incidence of congestive heart failure hospitalization (CHF) Time: 5 to 9 yearsDescription: The risk of a MACE event will be based on participant-time data, specifically, the number of events per participant years.
Measure: Incidence of a three-point MACE Time: 5 to 9 yearsDescription: The risk of a PVD event will be based on participant-time data, specifically, the number of events per participant years.
Measure: Incidence of a peripheral vascular disease (PVD) Time: 5 to 9 yearsDescription: Percentage of participants with 50% reduction in UACR from baseline
Measure: Percentage of participants with 50% reduction in UACR from baseline Time: 5 to 9 yearsDescription: Rate of change in eGFR per year during the study period.
Measure: Rate of change in eGFR per year during the study period Time: 5 to 9 years